Mixed Gel of Hydrocortisone and Aluminium Phosphate Preventing Endoscopic Submucosal Dissection Postoperative Stenosis for Patients With Large Esophageal Carcinoma
Primary Purpose
Esophageal Stenosis Acquired
Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Hydrocortisone sodium succinate mixed with Aluminium Phosphate gel (route of administration)
Triamcinolone Acetonide (route of administration)
Prednisone (route of administration)
Sponsored by
About this trial
This is an interventional prevention trial for Esophageal Stenosis Acquired
Eligibility Criteria
Inclusion Criteria:
- early esophagus cancer,lesions confined to the mucosal layer,ESD treatment is feasible and the resection range is ≥ 2/3 esophageal perimeter
- age 18 years or older
- chest CT scan without lymph node metastasis
Exclusion Criteria:
- patients with early esophagus cancer do not agree with endoscopic treatment
- occurrence of perforation in ESD requires further treatment
- lesions invading the muscularis mucosa and below
- postoperative pathologic assessment of ESD prompting incomplete resection and requiring radiotherapy and chemotherapy
Sites / Locations
- Peking University Third Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
hydrocortisone group
prednisone grope
Arm Description
Outcomes
Primary Outcome Measures
Esophageal stenosis rate
Esophageal stenosis is defined as that the standard upper gastrointestinal endoscopy with the diameter of 9.2mm can not pass the esophageal lumen.
Secondary Outcome Measures
The rate of endoscopic balloon dilation and its therapeutic effect.
We will compare the rate of endoscopic balloon dilation and its therapeutic effect of the two groups
Healing condition of the wound
healing rate=(area of wound after surgery - remained wound area)/area of wound after surgery
Side effect of drugs
including hypertension、hyperglycemia、electrolyte imbalance etc
Full Information
NCT ID
NCT03165344
First Posted
April 7, 2017
Last Updated
January 18, 2021
Sponsor
Peking University Third Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03165344
Brief Title
Mixed Gel of Hydrocortisone and Aluminium Phosphate Preventing Endoscopic Submucosal Dissection Postoperative Stenosis for Patients With Large Esophageal Carcinoma
Official Title
Effectiveness Evaluation of Mixed Gel of Hydrocortisone and Aluminium Phosphate Preventing Endoscopic Submucosal Dissection Postoperative Stenosis for Patients With Early Esophageal Cancer Invading More Than 2/3 Esophageal Perimeter
Study Type
Interventional
2. Study Status
Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
February 10, 2017 (Actual)
Primary Completion Date
December 31, 2019 (Actual)
Study Completion Date
December 31, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Peking University Third Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Endoscopic submucosal dissection as the fastest growing endoscopic treatment technology in the past decade has been widely used in the treatment of early esophageal cancer and gastric cancer without local lymph node metastasis. The main complications of ESD treatment of early esophageal cancer are hemorrhage, perforation, postoperative esophageal stenosis, infection, etc. Postoperative esophageal stenosis is the most common and major complication after ESD treating patients with lesion involving more than 2/3 esophagus cycle. It is very important to prevent esophageal stricture after ESD. Glucocorticoid is gradually concerned by clinical research because it can inhibit local inflammatory response and reduce the formation of connective tissue in order to prevent postoperative stenosis. The specific usages include endoscopic injection of corticosteroids, oral corticosteroids and combination of them. The study shows that the incidence of esophageal stricture after using glucocorticoid can be reduced effectively. Currently, there is no uniform consensus on the use of glucocorticoids, such as specific drugs, dosage, course of treatment, route of administration. In particular, efficacy comparison of different routes of administration is laking. Studies have shown that endoscopic injection triamcinolone acetonide in some patients with intractable esophageal stricture is not very effective, but it can be treated with oral corticosteroids. Aluminium Phosphate Gel is a kind of neutral buffer. The main component aluminum phosphate can form a strong ion buffer system in acidic environment. The structure of its auxiliary components agar and pectin is similar to that of natural mucus. It forms a mucous layer in the esophagus to restore and protect the esophageal mucosa. Therefore, investigators assume the hydrocortisone sodium succinate aluminum phosphate mixed gel can be used for preventing postoperative ESD stenosis of patients with a large area of early esophageal cancer. This study will design a randomized controlled trial to compare the effect of oral hydrocortisone sodium succinate mixed Aluminium Phosphate Gel and local injection of triamcinolone acetonide plus oral prednisone for the prevention of ESD postoperative esophageal stricture in patients with a large area of early esophageal cancer.
Detailed Description
Endoscopic submucosal dissection as the fastest growing endoscopic treatment technology in the past decade has been widely used in the treatment of early esophageal cancer and gastric cancer without local lymph node metastasis. The main complications of ESD treatment of early esophageal cancer are hemorrhage, perforation, postoperative esophageal stenosis, infection, etc. Postoperative esophageal stenosis is the most common and major complication after ESD treating patients with lesion involving more than 2/3 esophagus cycle. It is very important to prevent esophageal stricture after ESD. Glucocorticoid is gradually concerned by clinical research because it can inhibit local inflammatory response and reduce the formation of connective tissue in order to prevent postoperative stenosis. The specific usages include endoscopic injection of corticosteroids, oral corticosteroids and combination of them. The study shows that the incidence of esophageal stricture after using glucocorticoid can be reduced effectively. Currently, there is no uniform consensus on the use of glucocorticoids, such as specific drugs, dosage, course of treatment, route of administration. In particular, efficacy comparison of different routes of administration is laking. Studies have shown that endoscopic injection triamcinolone acetonide in some patients with intractable esophageal stricture is not very effective, but it can be treated with oral corticosteroids. Aluminium Phosphate Gel is a kind of neutral buffer. The main component aluminum phosphate can form a strong ion buffer system in acidic environment. The structure of its auxiliary components agar and pectin is similar to that of natural mucus. It forms a mucous layer in the esophagus to restore and protect the esophageal mucosa. Therefore, investigators assume the hydrocortisone sodium succinate aluminum phosphate mixed gel can be used for preventing postoperative ESD stenosis of patients with a large area of early esophageal cancer. This study will design a randomized controlled trial to compare the effect of oral hydrocortisone sodium succinate mixed Aluminium Phosphate Gel and local injection of triamcinolone acetonide plus oral prednisone for the prevention of ESD postoperative esophageal stricture in patients with a large area of early esophageal cancer.
The investigators will recruit patients according to admission criteria and exclusion criteria. The patients will be randomly divided into oral hydrocortisone mixed Aluminium Phosphate gel group (experimental group) and local injection of triamcinolone acetonide plus oral prednisone group (control group). The test group begin to take hydrocortisone sodium succinate mixed with Aluminium Phosphate gel after 24 hours and gradually reduse the dose. The control group will get local injection of triamcinolone acetonide in wound during the operation, and begin to take oral prednisone after 24 hours and gradually reduse the dose. The main result is esophageal stenosis rate 3 months after ESD.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Esophageal Stenosis Acquired
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
66 (Actual)
8. Arms, Groups, and Interventions
Arm Title
hydrocortisone group
Arm Type
Experimental
Arm Title
prednisone grope
Arm Type
Placebo Comparator
Intervention Type
Other
Intervention Name(s)
Hydrocortisone sodium succinate mixed with Aluminium Phosphate gel (route of administration)
Intervention Description
the test group begin to take hydrocortisone sodium succinate mixed with Aluminium Phosphate gel after 24 hours and gradually reduse the dose.
Intervention Type
Other
Intervention Name(s)
Triamcinolone Acetonide (route of administration)
Intervention Description
The control group will get local injection of triamcinolone acetonide in wound during the operation.
Intervention Type
Other
Intervention Name(s)
Prednisone (route of administration)
Intervention Description
The control group begin to take oral prednisone after 24 hours and gradually reduse the dose.
Primary Outcome Measure Information:
Title
Esophageal stenosis rate
Description
Esophageal stenosis is defined as that the standard upper gastrointestinal endoscopy with the diameter of 9.2mm can not pass the esophageal lumen.
Time Frame
3 months after ESD
Secondary Outcome Measure Information:
Title
The rate of endoscopic balloon dilation and its therapeutic effect.
Description
We will compare the rate of endoscopic balloon dilation and its therapeutic effect of the two groups
Time Frame
3 months after ESD
Title
Healing condition of the wound
Description
healing rate=(area of wound after surgery - remained wound area)/area of wound after surgery
Time Frame
3 months after ESD
Title
Side effect of drugs
Description
including hypertension、hyperglycemia、electrolyte imbalance etc
Time Frame
3 months after ESD
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
early esophagus cancer,lesions confined to the mucosal layer,ESD treatment is feasible and the resection range is ≥ 2/3 esophageal perimeter
age 18 years or older
chest CT scan without lymph node metastasis
Exclusion Criteria:
patients with early esophagus cancer do not agree with endoscopic treatment
occurrence of perforation in ESD requires further treatment
lesions invading the muscularis mucosa and below
postoperative pathologic assessment of ESD prompting incomplete resection and requiring radiotherapy and chemotherapy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yonghui Huang, archiater
Organizational Affiliation
Peking University Third Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Peking University Third Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100000
Country
China
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
21296855
Citation
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. Erratum In: CA Cancer J Clin. 2011 Mar-Apr;61(2):134.
Results Reference
result
PubMed Identifier
25031273
Citation
Merkow RP, Bilimoria KY, Keswani RN, Chung J, Sherman KL, Knab LM, Posner MC, Bentrem DJ. Treatment trends, risk of lymph node metastasis, and outcomes for localized esophageal cancer. J Natl Cancer Inst. 2014 Jul 16;106(7):dju133. doi: 10.1093/jnci/dju133. Print 2014 Jul.
Results Reference
result
PubMed Identifier
19302207
Citation
Mizuta H, Nishimori I, Kuratani Y, Higashidani Y, Kohsaki T, Onishi S. Predictive factors for esophageal stenosis after endoscopic submucosal dissection for superficial esophageal cancer. Dis Esophagus. 2009;22(7):626-31. doi: 10.1111/j.1442-2050.2009.00954.x. Epub 2009 Mar 6.
Results Reference
result
PubMed Identifier
19565442
Citation
Ono S, Fujishiro M, Niimi K, Goto O, Kodashima S, Yamamichi N, Omata M. Predictors of postoperative stricture after esophageal endoscopic submucosal dissection for superficial squamous cell neoplasms. Endoscopy. 2009 Aug;41(8):661-5. doi: 10.1055/s-0029-1214867. Epub 2009 Jun 29.
Results Reference
result
PubMed Identifier
24830402
Citation
Shi Q, Ju H, Yao LQ, Zhou PH, Xu MD, Chen T, Zhou JM, Chen TY, Zhong YS. Risk factors for postoperative stricture after endoscopic submucosal dissection for superficial esophageal carcinoma. Endoscopy. 2014 Aug;46(8):640-4. doi: 10.1055/s-0034-1365648. Epub 2014 May 15.
Results Reference
result
PubMed Identifier
24512802
Citation
Hochberger J, Koehler P, Wedi E, Gluer S, Rothstein RI, Niemann H, Hilfiker A, Gonzalez S, Kruse E. Transplantation of mucosa from stomach to esophagus to prevent stricture after circumferential endoscopic submucosal dissection of early squamous cell. Gastroenterology. 2014 Apr;146(4):906-9. doi: 10.1053/j.gastro.2014.01.063. Epub 2014 Feb 8. No abstract available.
Results Reference
result
PubMed Identifier
22638783
Citation
Machida H, Tominaga K, Minamino H, Sugimori S, Okazaki H, Yamagami H, Tanigawa T, Watanabe K, Watanabe T, Fujiwara Y, Arakawa T. Locoregional mitomycin C injection for esophageal stricture after endoscopic submucosal dissection. Endoscopy. 2012 Jun;44(6):622-5. doi: 10.1055/s-0032-1306775. Epub 2012 May 25.
Results Reference
result
PubMed Identifier
21492854
Citation
Yamaguchi N, Isomoto H, Nakayama T, Hayashi T, Nishiyama H, Ohnita K, Takeshima F, Shikuwa S, Kohno S, Nakao K. Usefulness of oral prednisolone in the treatment of esophageal stricture after endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma. Gastrointest Endosc. 2011 Jun;73(6):1115-21. doi: 10.1016/j.gie.2011.02.005. Epub 2011 Apr 14.
Results Reference
result
PubMed Identifier
22930171
Citation
Hanaoka N, Ishihara R, Takeuchi Y, Uedo N, Higashino K, Ohta T, Kanzaki H, Hanafusa M, Nagai K, Matsui F, Iishi H, Tatsuta M, Ito Y. Intralesional steroid injection to prevent stricture after endoscopic submucosal dissection for esophageal cancer: a controlled prospective study. Endoscopy. 2012 Nov;44(11):1007-11. doi: 10.1055/s-0032-1310107. Epub 2012 Aug 28.
Results Reference
result
PubMed Identifier
22136782
Citation
Hashimoto S, Kobayashi M, Takeuchi M, Sato Y, Narisawa R, Aoyagi Y. The efficacy of endoscopic triamcinolone injection for the prevention of esophageal stricture after endoscopic submucosal dissection. Gastrointest Endosc. 2011 Dec;74(6):1389-93. doi: 10.1016/j.gie.2011.07.070.
Results Reference
result
PubMed Identifier
18704454
Citation
Morikawa N, Honna T, Kuroda T, Watanabe K, Tanaka H, Takayasu H, Fujino A, Tanemura H, Matsukubo M. High dose intravenous methylprednisolone resolves esophageal stricture resistant to balloon dilatation with intralesional injection of dexamethasone. Pediatr Surg Int. 2008 Oct;24(10):1161-4. doi: 10.1007/s00383-008-2224-7.
Results Reference
result
PubMed Identifier
19430800
Citation
Hishiki T, Kouchi K, Saito T, Terui K, Sato Y, Mitsunaga T, Nakata M, Yoshida H. Successful treatment of severe refractory anastomotic stricture in an infant after esophageal atresia repair by endoscopic balloon dilation combined with systemic administration of dexamethasone. Pediatr Surg Int. 2009 Jun;25(6):531-3. doi: 10.1007/s00383-009-2367-1. Epub 2009 May 9.
Results Reference
result
Learn more about this trial
Mixed Gel of Hydrocortisone and Aluminium Phosphate Preventing Endoscopic Submucosal Dissection Postoperative Stenosis for Patients With Large Esophageal Carcinoma
We'll reach out to this number within 24 hrs